Invesco Ltd. Increases Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Invesco Ltd. grew its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 692,464 shares of the company's stock after acquiring an additional 67,285 shares during the quarter. Invesco Ltd. owned 1.43% of Axsome Therapeutics worth $58,589,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. ADAR1 Capital Management LLC grew its stake in Axsome Therapeutics by 3,176.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 19,661 shares of the company's stock worth $1,664,000 after buying an additional 19,061 shares in the last quarter. Cerity Partners LLC boosted its position in shares of Axsome Therapeutics by 32.0% during the 4th quarter. Cerity Partners LLC now owns 4,941 shares of the company's stock worth $419,000 after acquiring an additional 1,198 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Axsome Therapeutics by 1,815.0% in the fourth quarter. Russell Investments Group Ltd. now owns 19,437 shares of the company's stock valued at $1,645,000 after acquiring an additional 18,422 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Axsome Therapeutics by 74.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 35,129 shares of the company's stock valued at $2,972,000 after acquiring an additional 15,047 shares during the last quarter. Finally, Pitcairn Co. raised its position in Axsome Therapeutics by 3.4% during the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company's stock valued at $386,000 after purchasing an additional 148 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Trading Down 0.0 %

Shares of AXSM stock traded down $0.01 during mid-day trading on Friday, hitting $104.46. The company's stock had a trading volume of 486,786 shares, compared to its average volume of 681,903. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company's fifty day simple moving average is $118.71 and its 200-day simple moving average is $102.30. The company has a market cap of $5.09 billion, a PE ratio of -17.44 and a beta of 0.88.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.40% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Needham & Company LLC reissued a "buy" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Royal Bank of Canada upped their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a report on Wednesday, February 19th. Jefferies Financial Group assumed coverage on Axsome Therapeutics in a research note on Monday, April 7th. They set a "buy" rating and a $200.00 price target on the stock. Finally, Morgan Stanley upped their price objective on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $169.80.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.